Global PD-L1 Biomarker Testing Market Strategic Research Report

Scope of the Report

The global PD-L1 Biomarker Testing market size is predicted to grow from US$ 3,906 million in 2025 to US$ 36,040 million in 2032; it is expected to grow at a CAGR of 37.8% from 2026 to 2032.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart). PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies. PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The PD‑L1 biomarker testing market is being propelled by the rapid expansion of immune checkpoint inhibitor therapies, particularly those targeting the PD‑1/PD‑L1 axis, which have shown remarkable clinical success in treating various advanced cancers—spurring widespread demand for stratifying patients based on PD‑L1 expression to optimize treatment outcomes. Additionally, the shift toward precision medicine has heightened the importance of molecular diagnostics. Clinicians and pharmaceutical developers are increasingly emphasizing personalized approaches, using PD‑L1 testing to guide therapeutic decisions and enable companion diagnostics—especially as diagnostic technologies advance to include automated IHC systems, NGS platforms, and AI-enhanced analysis.

Despite these positive trends, the PD‑L1 testing landscape faces significant obstacles due to a lack of standardization across protocols, assay clones, scoring systems, and cut-off thresholds. This inconsistency manifests in discordant results (with variability rates reported between 19–32% across different assays), undermining diagnostic reliability and complicating clinical decision-making. Moreover, high costs associated with advanced testing techniques (IHC, NGS) and uneven reimbursement frameworks create economic barriers, particularly in developing regions, impeding broad accessibility and exacerbating healthcare disparities.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2024 is about 21.68%. PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.

This report presents a comprehensive overview of the global PD-L1 Biomarker Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• PD-L1 (22C3)
• PD-L1(28-8)
• PD-L1 (SP142)
• PD-L1 (SP263)
• Other

Segment by players, this report covers

• Agilent Technologies
• Roche
• Merck
• Bristol-Myers Squibb
• AstraZeneca
• Ono Pharmaceutical
• Regeneron
• Innovent
• Hengrui Medicine
• Junshi Biosciences

Segment by Application

• Hospital
• Diagnostic Center
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global PD-L1 Biomarker Testing market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Diagnostic Center, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact